Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway
Open Access
- 21 December 2009
- journal article
- Published by Springer Nature in BMC Cell Biology
- Vol. 10 (1) , 94
Abstract
Background: Epithelial to Mesenchymal Transition (EMT) induced by Transforming Growth Factor-β (TGF-β) is an important cellular event in organogenesis, cancer, and organ fibrosis. The process to reverse EMT is not well established. Our purpose is to define signaling pathways and transcription factors that maintain the TGF-β-induced mesenchymal state. Results: Inhibitors of five kinases implicated in EMT, TGF-β Type I receptor kinase (TβRI), p38 mitogen-activated protein kinase (p38 MAPK), MAP kinase kinase/extracellular signal-regulated kinase activator kinase (MEK1), c-Jun NH-terminal kinase (JNK), and Rho kinase (ROCK), were evaluated for reversal of the mesenchymal state induced in renal tubular epithelial cells. Single agents did not fully reverse EMT as determined by cellular morphology and gene expression. However, exposure to the TβRI inhibitor SB431542, combined with the ROCK inhibitor Y27632, eliminated detectable actin stress fibers and mesenchymal gene expression while restoring epithelial E-cadherin and Kidney-specific cadherin (Ksp-cadherin) expression. A second combination, the TβRI inhibitor SB431542 together with the p38 MAPK inhibitor SB203580, was partially effective in reversing EMT. Furthermore, JNK inhibitor SP600125 inhibits the effectiveness of the TβRI inhibitor SB431542 to reverse EMT. To explore the molecular basis underlying EMT reversal, we also targeted the transcriptional repressors ZEB1 and ZEB2/SIP1. Decreasing ZEB1 and ZEB2 expression in mouse mammary gland cells with shRNAs was sufficient to up-regulate expression of epithelial proteins such as E-cadherin and to re-establish epithelial features. However, complete restoration of cortical F-actin required incubation with the ROCK inhibitor Y27632 in combination with ZEB1/2 knockdown. Conclusions: We demonstrate that reversal of EMT requires re-establishing both epithelial transcription and structural components by sustained and independent signaling through TβRI and ROCK. These findings indicate that combination small molecule therapy targeting multiple kinases may be necessary to reverse disease conditions.Keywords
This publication has 85 references indexed in Scilit:
- TGFβ in CancerCell, 2008
- Epithelial-to-mesenchymal transition and chronic allograft tubulointerstitial fibrosisTransplantation Reviews, 2008
- The transcription factor ZEB1 (δEF1) represses Plakophilin 3 during human cancer progressionFEBS Letters, 2007
- Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2Nature Cell Biology, 2007
- Development of TGF-β signalling inhibitors for cancer therapyNature Reviews Drug Discovery, 2004
- New insights into TGF-β–Smad signallingTrends in Biochemical Sciences, 2004
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003
- Attenuation of the TGF-β-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-β-induced growth arrestOncogene, 2003
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cellsNature Cell Biology, 2000